Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
65
RLAY Quote, Financials, Valuation and Earnings
Last price:
$8.66
Seasonality move
:
-13.11%
Day range:
$8.31 - $8.76
52-week range:
$1.78 - $9.04
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
169.12x
P/B ratio:
2.37x
Volume:
1.4M
Avg. volume:
2.3M
1-year change:
104.49%
Market cap:
$1.4B
Revenue:
$10M
EPS (TTM):
-$1.75
Analysts' Opinion
-
Consensus RatingRelay Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 9 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $14.60, Relay Therapeutics, Inc. has an estimated upside of 75.69% from its current price of $8.65.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $12.00 representing 100% downside risk from its current price of $8.65.
Fair Value
-
According to the consensus of 10 analysts, Relay Therapeutics, Inc. has 75.69% upside to fair value with a price target of $14.60 per share.
RLAY vs. S&P 500
-
Over the past 5 trading days, Relay Therapeutics, Inc. has underperformed the S&P 500 by -3.92% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Relay Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Relay Therapeutics, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Relay Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Relay Therapeutics, Inc. has grown year-over-year earnings for 4 quarters straight. In the most recent quarter Relay Therapeutics, Inc. reported earnings per share of -$0.43.
Enterprise value:
877.2M
EV / Invested capital:
1.37x
Price / LTM sales:
169.12x
EV / EBIT:
--
EV / Revenue:
104.98x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-3.52x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$4.1M
Return On Assets:
-37.2%
Net Income Margin (TTM):
-3561.43%
Return On Equity:
-41.21%
Return On Invested Capital:
-38.91%
Operating Margin:
-11351.11%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $25.8M | $10M | $8.4M | -- | -- | |
| Gross Profit | $20.7M | $4.5M | $4.1M | -$1.4M | -$748K | |
| Operating Income | -$368.6M | -$395M | -$327.1M | -$96.4M | -$80.4M | |
| EBITDA | -$363.5M | -$389.5M | -$322.8M | -$95M | -$79.6M | |
| Diluted EPS | -$2.68 | -$2.61 | -$1.75 | -$0.63 | -$0.43 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $639.3M | $1.1B | $831.8M | $865.1M | $624M | |
| Total Assets | $671.6M | $1.2B | $907M | $930.1M | $670M | |
| Current Liabilities | $28.5M | $71.4M | $50.7M | $47M | $32.6M | |
| Total Liabilities | $100.5M | $168.9M | $128.6M | $91.3M | $62.3M | |
| Total Equity | $571.1M | $999.8M | $778.4M | $838.9M | $607.7M | |
| Total Debt | $21.5M | $54.6M | $49.8M | $44.3M | $29.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$268.2M | -$280.4M | -$248.5M | -$75.1M | -$62.1M | |
| Cash From Investing | $51M | -$10.4M | $186.3M | -$126.2M | $39.7M | |
| Cash From Financing | $14M | $291.3M | $1.5M | $218.9M | $17K | |
| Free Cash Flow | -$274.5M | -$282.6M | -$248.9M | -$75.3M | -$62.1M | |
RLAY
Sector
Market Cap
$1.4B
$28.1M
Price % of 52-Week High
91.93%
51.39%
Dividend Yield
0%
0%
Shareholder Yield
0.23%
-1.49%
1-Year Price Total Return
91.48%
-17.13%
Beta (5-Year)
1.501
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$8.39
200-day SMA
Buy
Level
$4.48
Bollinger Bands (100)
Buy
Level
4.09 - 7.51
Chaikin Money Flow
Sell
Level
-1.3M
20-day SMA
Buy
Level
$8.00
Relative Strength Index (RSI14)
Buy
Level
63.82
ADX Line
Buy
Level
12.99
Williams %R
Neutral
Level
-45.0617
50-day SMA
Buy
Level
$7.28
MACD (12, 26)
Buy
Level
2.22
25-day Aroon Oscillator
Buy
Level
76
On Balance Volume
Neutral
Level
9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.2373)
Sell
CA Score
(Annual)
Level (-0.6894)
Buy
Beneish M-Score
(Annual)
Level (-4.3822)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (4.553)
Sell
Piotroski F Score
(Annual)
Level (3)
Sell
Quality Ratio Score
Level (3)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its Dynamo platform is use to integrate an array of edge experimental and computational approaches, which allows to apply the understanding of protein structure and motion to drug discovery. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.
Stock Forecast FAQ
In the current month, RLAY has received 9 Buy ratings 1 Hold ratings, and 0 Sell ratings. The RLAY average analyst price target in the past 3 months is $14.60.
-
Where Will Relay Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Relay Therapeutics, Inc. share price will rise to $14.60 per share over the next 12 months.
-
What Do Analysts Say About Relay Therapeutics, Inc.?
Analysts are divided on their view about Relay Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Relay Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $12.00.
-
What Is Relay Therapeutics, Inc.'s Price Target?
The price target for Relay Therapeutics, Inc. over the next 1-year time period is forecast to be $14.60 according to 10 Wall Street analysts, 9 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is RLAY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Relay Therapeutics, Inc. is a Buy. 9 of 10 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of RLAY?
You can purchase shares of Relay Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Relay Therapeutics, Inc. shares.
-
What Is The Relay Therapeutics, Inc. Share Price Today?
Relay Therapeutics, Inc. was last trading at $8.66 per share. This represents the most recent stock quote for Relay Therapeutics, Inc.. Yesterday, Relay Therapeutics, Inc. closed at $8.65 per share.
-
How To Buy Relay Therapeutics, Inc. Stock Online?
In order to purchase Relay Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get RLAY Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
RLAY
Sector
P/E ratio
--
23.89x
PEG ratio
--
-0.01x
P/B ratio
2.37x
1.81x
Price / LTM sales
169.12x
1.59x
Growth Metrics
RLAY
Sector
Revenue growth
-23.26%
4.62%
Earnings growth
31.55%
11.06%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$0.42
-$0.21
Profitability
RLAY
Sector
Profitability FY 2024
$4.5M
$3.6M
Return on invested capital
-38.91%
-31.84%
Return on assets
-37.2%
-27.96%
Return on equity
-41.21%
-37.63%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Feb
25
Estimated Next Earnings Date
Feb
5
Balance Sheet
RLAY
Sector
Total cash
$596.4M
$26.4M
Short term investments
$657M
$25.7M
Total assets
$871.3M
$76.9M
Long term debt
$29.7M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
85
HUT alert for Dec 25
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
63
GPCR alert for Dec 25
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
